Pharmacological Profile of 6,12-Dihydro-3-methoxy-1-benzopyrano [3,4-b][1,4] benzothiazin-6-one, a Novel Human Estrogen Receptor Agonist

概要

論文の詳細を見る
Pharmacological studies were carried out to characterize further the endocrinological profile and the binding mode to the estrogen receptor (ER) of 6,12-dihydro-3-methoxy-1-benzopyrano[3,4-b][1,4]benzothiazin-6-one (1). Binding experiments were conducted with highly purified recombinant human estrogen receptors hERα and β. Potent estrogenic activity of compound 1 was assessed by testing its ability to down-regulate ERs and to enhance estrogen receptor element (ERE)-dependent transcription. The latest step of our work dealt with the synthesis of the 9-fluorinated derivative 15 for ionic microscopy experiments to determine the intracellular localization of compound 1. Although 1 failed to compete with [^3H]E_2 for binding to both ER isoforms, evidence was reported that it interacted with hERα in MCF-7 cells (ER down-regulation/ERE-dependent luciferase induction). Hence, an appropriate conformation of the hormone binding domain, most probably conferred by co-regulators of ER, is required for the onset of an activity of the compound 1. Estrogenic activity was weak but on the order of magnitude of that of coumestrol (slightly weaker). The synthesis of the 9-methoxylated derivative 16 and its pharmacological evaluation led us to propose a binding mode of 1 on hERα. Compound 1 appears to interact with ERα mainly through interactions of its 3-methoxy substituent with the residue His-524 of the hormone binding domain.
公益社団法人日本薬学会の論文
2002-03-01

Pharmacological Profile of 6,12-Dihydro-3-methoxy-1-benzopyrano [3,4-b][1,4] benzothiazin-6-one, a Novel Human Estrogen Receptor Agonist

スポンサーリンク

概要

著者

関連論文

スポンサーリンク